Lonza (Basel, Switzerland, www.lonza.com) purchased Zyentia's (Cambridge, UK, www.zyentia.com) Aggresolve technology, a comprehensive in silico protein analysis platform that can be applied to problem solving of protein aggregation, for an undisclosed sum.
Lonza (Basel, Switzerland, www.lonza.com) purchased Zyentia’s (Cambridge, UK, www.zyentia.com) Aggresolve technology, a comprehensive in silico protein analysis platform that can be applied to problem solving of protein aggregation, for an undisclosed sum.
Aggresolve can be used to screen proteins to predict aggregation problems, to predict sequence changes likely to reduce aggregation, and to design aggregation inhibitors and stabilizers. The technology will be incorporated into a new group headed by Jesus Zurdo, PhD, one of the inventors of the technology.
Novartis Acquisition of Regulus Therapeutics is Complete
June 25th 2025A key property included in the acquisition is farabursen, an investigational next-generation oligonucleotide targeting the microRNA miR-17 with preferential kidney exposure, intended to treat people with autosomal dominant polycystic kidney disease.